공시 • Sep 04
Daxor Corporation's Blood Volume Analysis Validated for Covid and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care
Daxor Corporation highlighted the significant findings of a new pilot study published in the Journal of Critical Care. Co-authored by leading intensive care expert Jan Bakker, M.D., Ph.D., this pivotal research reveals frequent inaccuracies in how doctors clinically assess fluid levels in critically ill patients with sepsis and COVID-19. The research, titled, "Endothelial dysfunction in critically ill patients with sePSis and COVID-19 using the albumin transudation rate: A pilot study," found that patients were often misclassified during clinical assessment, with many mistakenly believed to be " hypervolemic" (fluid overloaded) when objective measurements showed them to be "hypovolemic" (fluid deficient), and vice-versa. For instance, 48% of COVID-19 patients were clinically deemed hypervolemic when objective hypovolemic, and clinicians often misclassified sepsis patients as euvolemic or hypervolemic when they were hypovolemic when they were hypvolemic; Persistent Capillary Leakage: The study showed that " albumin transudation rate (ATR"), a measure of fluid leaking from blood vessels into tissues, was persistently elevated in both sepsis and COVID -19 patients throughout their ICU stay; Higher Leakage in Sepsis: Patients with sepsis exhibited significantly higher ATR than those with COVID-19, indicating a more severe and sustained breakdown in blood vessel integrity in sepsis, despite often having lower admission severity scores; Urgent Need for Better Tools: The study concludes there is a "frequent inaccuracy in clinical fluid status assessment, which demands more reliable diagnostic tools to better guide fluid therapy in critically ill patients" Daxor's FDA-approved BVA-100™? Analyzer was utilized in this study to objectively measure total blood volume and albumin transudation rates. The findings highlight the immense promise of Daxor's Blood Volume Analysis (BVA) technology in the Intensive Care Unit (ICU) and critical care settings. The need for rapid and accurate diagnostics in critical care is now more pressing than ever. This new research, coupled with Daxor's recent FDA Clearance in August 2025 for its new rapid, lightweight, battery operated BVA system, positions Daxor to address this critical medical challenge. This next-generation analyzer, which is three times faster than the BVA-100™? but still over 95% accurate and simpler, delivers blood volume results at a speed crucial for interventions in the ICU. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor's patented, FDA-cleared Blood Volume Analysis (BVA") diagnostic offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with post-market clinical data collection activities, benefits of products to patients,exexexexexexa.